{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T01:04:05Z","timestamp":1785805445198,"version":"3.56.0"},"reference-count":54,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T00:00:00Z","timestamp":1663891200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Pentavalent antimonials (PAs) are the primary therapeutic option for American tegumentary leishmaniasis (ATL). However, the use of these drugs is complicated by adverse events (AEs), resistance and contraindications. Alternative therapies relative effectiveness is not well established.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>This study compared the effectiveness of liposomal amphotericin B (LAB) with intravenous meglumine antimoniate (NMG) in the treatment of ATL. We also analysed and compared associated AEs and treatment interruption rates.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This was a retrospective cohort study from Brazil. The potential risk factors for the primary outcome were age, sex, total cutaneous lesion area, presence of mucosal lesions, AEs and treatment interruption. The primary outcome was lesion healing within 6 months of treatment. AEs and treatment interruption were also analysed. Multiple analytic strategies were employed to evaluate the reliability of the results.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Before propensity score (PS) matching, patients in the LAB group were older and had a higher frequency of mucosal lesions. The NMG group had a higher cure rate than the LAB group (cure rate 88% versus 55% respectively) in the adjusted analysis (relative risk (RR)=1.55 95% CI: 1.19 - 2.02) and after PS matching (RR=1.63 95% CI: 1.20 - 2.21). NMG group had a higher AE rate (event rate 52% versus 44%) in the adjusted analysis (RR= 1.61, 95% CI: 1.06 - 2.43, p=0.02), but this result was not observed after PS matching (RR= 0.87, 95% CI: 0.49 -1.52, p= 0.61).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>We observed that the NMG group had a higher cure rate than the LAB group, with an equivocally higher EV rate in the adjusted analysis.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcimb.2022.993338","type":"journal-article","created":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T11:10:23Z","timestamp":1663931423000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Meglumine antimoniate was associated with a higher cure rate than liposomal amphotericin B in the treatment of American tegumentary leishmaniasis: A retrospective cohort study from a Leishmania braziliensis-endemic area"],"prefix":"10.3389","volume":"12","author":[{"given":"Daniel Holanda","family":"Barroso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata Trindade","family":"Gon\u00e7alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joadyson Silva","family":"Barbosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorgeth de Oliveira Carneiro","family":"da Motta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo Subtil Magalh\u00e3es","family":"Freire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciro Martins","family":"Gomes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raimunda Nonata Ribeiro","family":"Sampaio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"818","DOI":"10.4269\/ajtmh.2011.11-0287","article-title":"Can we use a lower dose of liposomal amphotericin b for the treatment of mucosal American leishmaniasis","volume":"85","author":"Amato","year":"2011","journal-title":"Am. J. Trop. Med. Hygiene"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1017\/S0022215110001325","article-title":"Risk factors associated with dizziness during treatment of mucosal leishmaniasis with meglumine antimoniate: 16-year retrospective study of cases from Rio de Janeiro, Brazil","volume":"124","author":"Araujo-Melo","year":"2010","journal-title":"J. Laryngology Otology"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e202","DOI":"10.1093\/cid\/ciw670","article-title":"Diagnosis and treatment of leishmaniasis: clinical practice guidelines by the infectious diseases society of America (IDSA) and the American society of tropical medicine and hygiene (ASTMH)","volume":"63","author":"Aronson","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"B4","doi-asserted-by":"publisher","first-page":"24","DOI":"10.4269\/ajtmh.16-84256","article-title":"Diagnosis and treatment of leishmaniasis: Clinical practice guidelines by the infectious diseases society of America (IDSA) and the American society of tropical medicine and hygiene (ASTMH)","volume":"96","author":"Aronson","year":"2017","journal-title":"Am. J. Trop. Med. Hygiene"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1056\/NEJM200006223422506","article-title":"A comparison of observational studies and randomized, controlled trials","volume":"342","author":"Benson","year":"2000","journal-title":"New Engl. J. Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1093\/clinids\/10.3.560","article-title":"Chemotherapy for leishmaniasis: biochemical mechanisms, clinical efficacy, and future strategies","volume":"10","author":"Berman","year":"1988","journal-title":"Rev. Infect. Dis."},{"key":"B7","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S0140-6736(18)31204-2","article-title":"Leishmaniasis","volume":"392","author":"Burza","year":"2018","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","first-page":"847","DOI":"10.4269\/ajtmh.2011.10-0693","article-title":"A cluster of cutaneous leishmaniasis associated with human smuggling","volume":"84","author":"Cannella","year":"2011","journal-title":"Am. J. Trop. Med. Hygiene"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.4269\/ajtmh.14-0631","article-title":"Age modifies the immunologic response and clinical presentation of American tegumentary leishmaniasis","volume":"92","author":"Carvalho","year":"2015","journal-title":"Am. J. Trop. Med. Hyg"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.4269\/ajtmh.15-0033","article-title":"Efficacy and safety of liposomal amphotericin b for the treatment of mucosal leishmaniasis from the new world: A retrospective study","volume":"93","author":"Cunha","year":"2015","journal-title":"Am. J. Trop. Med. Hyg"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e12874","DOI":"10.1111\/pim.12874","article-title":"Influence of sex hormones on the immune response to leishmaniasis","volume":"43","author":"de Ara\u00fajo Albuquerque","year":"2021","journal-title":"Parasite Immunol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1590\/S0037-86822012000500011","article-title":"The effect of age on the frequency of adverse reactions caused by antimony in the treatment of American tegumentary leishmaniasis in governador valadares, state of minas gerais, Brazil","volume":"45","author":"Diniz","year":"2012","journal-title":"Rev. da Sociedade Bras. Medicina Trop."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.4269\/ajtmh.17-0736","article-title":"The elderly respond to antimony therapy for cutaneous leishmaniasis similarly to young patients but have severe adverse reactions","volume":"98","author":"do Lago","year":"2018","journal-title":"Am Trop Med Hygiene"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S0265021506001967","article-title":"Clinical research in anaesthesia; randomized controlled trials or observational studies","volume":"24","author":"Feneck","year":"2007","journal-title":"Eur. J. Anaesthesiology"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0009003","article-title":"Risk factors for antimony treatment failure in American cutaneous leishmaniasis in northwestern-Argentina","volume":"15","author":"Garc\u00eda-Bustos","year":"2021","journal-title":"PLoS Negl. Trop. Dis."},{"key":"B16","volume-title":"Acur\u00e1cia da rea\u00e7\u00e3o em cadeia da polimerase em amostras de saliva, swab nasal e papel filtro oral no diagn\u00f3stico da leishmaniose tegumentar americana: estudo cl\u00ednico, revis\u00e3o sistem\u00e1tica da literatura e meta-an\u00e1lise","author":"Gomes","year":"2014"},{"key":"B17","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1590\/abd1806-4841.20142389","article-title":"Complementary exams in the diagnosis of American tegumentary leishmaniasis","volume":"89","author":"Gomes","year":"2014","journal-title":"Bras. Dermatol."},{"key":"B18","first-page":"CD004834","article-title":"Interventions for American cutaneous and mucocutaneous leishmaniasis","volume-title":"Cochrane Database  Systematic Rev","author":"Gonz\u00e1lez","year":"2009"},{"key":"B19","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3844\/ajidsp.2014.167.173","article-title":"New World Mucocutaneous Leishmaniasis with Oral Manifestations: Case Report and Damage Repair","volume":"10","author":"Gord\u00f3n-N\u00fa\u00f1ez","year":"2014","journal-title":"Am J  Infectious Dis"},{"key":"B20","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1017\/S026646231800034X","article-title":"Comparative effectiveness and safety between amphotericin b lipid-formulations: a systematic review","volume":"34","author":"Grazziotin","year":"2018","journal-title":"Int. J. Technol. Assess. Health Care"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e0006094","DOI":"10.1371\/journal.pntd.0006094","article-title":"Liposomal amphotericin b in travelers with cutaneous and muco-cutaneous leishmaniasis: Not a panacea","volume":"11","author":"Guery","year":"2017","journal-title":"PLoS Negl. Trop. Dis."},{"key":"B22","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1086\/382077","article-title":"Combating tropical infectious diseases: report of the disease control priorities in developing countries project","volume":"38","author":"Hotez","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"B23","doi-asserted-by":"publisher","first-page":"426","DOI":"10.4269\/ajtmh.2012.11-0378","article-title":"Epidemiological and clinical changes in American tegumentary leishmaniasis in an area of leishmania (Viannia) braziliensis transmission over a 20-year period","volume":"86","author":"Jirmanus","year":"2012","journal-title":"Am. J. Trop. Med. Hygiene"},{"key":"B24","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ijantimicag.2006.03.013","article-title":"What is the current and future status of conventional amphotericin b","volume":"27","author":"Kleinberg","year":"2006","journal-title":"Int. J. antimicrobial Agents"},{"key":"B25","first-page":"259","article-title":"Morte ap\u00f3s uso de antimonial pentavalente em leishmaniose tegumentar americana","volume":"261","author":"Kopke","year":"1993","journal-title":"An. Bras. Dermatol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1590\/S0365-05962007000200002","article-title":"Tratamento da leishmaniose tegumentar americana","volume":"82","author":"Lima","year":"2007","journal-title":"An. Bras. Dermatol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1590\/S1678-9946201658068","article-title":"Pancreatic toxicity as an adverse effect induced by meglumine antimoniate therapy in a clinical trial for cutaneous leishmaniasis","volume":"58","author":"Lyra","year":"2016","journal-title":"Rev. do Instituto Medicina Trop. S\u00e3o Paulo"},{"key":"B28","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.trstmh.2003.08.001","article-title":"Risk factors for mucosal manifestation of American cutaneous leishmaniasis","volume":"99","author":"Machado-Coelho","year":"2005","journal-title":"Trans. R Soc. Trop. Med. Hyg"},{"key":"B29","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1111\/j.1601-0825.2006.01296.x","article-title":"Oral leishmaniasis: a clinicopathological study of 11 cases","volume":"13","author":"Motta","year":"2007","journal-title":"Oral. Dis."},{"key":"B30","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1111\/j.1468-3083.2011.04070.x","article-title":"A pilot study comparing low-dose liposomal amphotericin b with n-methyl glucamine for the treatment of American cutaneous leishmaniasis","volume":"26","author":"Motta","year":"2012","journal-title":"J. Eur. Acad. Dermatol. Venereology"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1590\/s0365-05962011000600005","article-title":"A randomized clinical trial comparing meglumine antimoniate, pentamidine and amphotericin b for the treatment of cutaneous leishmaniasis by leishmania guyanensis","volume":"86","author":"Neves","year":"2011","journal-title":"Bras. Dermatol."},{"key":"B32","first-page":"51","article-title":"Estudo hospitalar de leishmaniose tegumentar americana (LTA): epidemiologia e tratamento","volume":"76","author":"Nogueira","year":"2001","journal-title":"An. Bras. Dermatol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.actatropica.2011.02.007","article-title":"Systematic review of the adverse effects of cutaneous leishmaniasis treatment in the new world","volume":"118","author":"Oliveira","year":"2011","journal-title":"Acta Trop."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/14651858.CD004834.pub3","article-title":"Interventions for American cutaneous and mucocutaneous leishmaniasis","volume":"8","author":"Pinart","year":"2020","journal-title":"Cochrane Database Systematic Rev."},{"key":"B35","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1093\/ndt\/gfm433","article-title":"Clinical research of kidney diseases II: problems of study design","volume":"22","author":"Ravani","year":"2007","journal-title":"Nephrol. Dialysis Transplant."},{"key":"B36","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1093\/trstmh\/tru011","article-title":"Liposomal formulation of amphotericin b for the treatment of mucosal leishmaniasis in HIV-negative patients","volume":"108","author":"Rocio","year":"2014","journal-title":"Trans. R. Soc. Trop. Med. Hygiene"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1086\/374553","article-title":"Triad of acute infusion-related reactions associated with liposomal amphotericin b: analysis of clinical and epidemiological characteristics","volume":"36","author":"Roden","year":"2003","journal-title":"Clin. Infect. Dis."},{"key":"B38","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1111\/j.1365-4362.1971.tb01694.x","article-title":"Treatment of mucocutaneous (American) leishmaniasis with amphotericin b: report of 70 cases","volume":"10","author":"Sampaio","year":"1971","journal-title":"Int. J. Dermatol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1001\/archderm.1960.01580040145026","article-title":"The treatment of American (mucocutaneous) leishmaniasis with amphotericin b","volume":"82","author":"Sampaio","year":"1960","journal-title":"Arch. Dermatol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1590\/S0037-86821997000200007","article-title":"Treatment of the mucosal form of leishmaniasis without response to glucantime, with liposomal amphotericin b","volume":"30","author":"Sampaio","year":"1997","journal-title":"Rev. da Sociedade Bras. Medicina Trop."},{"key":"B41","article-title":"Manual for Surveillance of cutaneous leishmaniasis Biblioteca Virtual em Sa\u00fade do Minist\u00e9rio da Sa\u00fade","author":"Sa\u00fade","year":"2017"},{"key":"B42","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/bjd.18964","article-title":"American Cutaneous leishmaniasis in French Guiana: a retrospective comparison between liposomal amphotericin b and meglumine antimoniate","volume":"183","author":"Senchyna","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.4269\/ajtmh.20-0131","article-title":"Case report: coinfection by leishmania amazonensis and HIV in a Brazilian diffuse cutaneous leishmaniasis patient","volume":"103","author":"Soares","year":"2020","journal-title":"Am. J. Trop. Med. Hygiene"},{"key":"B44","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1111\/j.1468-3083.2010.03908.x","article-title":"Liposomal amphotericin b treatment of cutaneous leishmaniasis due to leishmania tropica","volume":"25","author":"Solomon","year":"2011","journal-title":"J. Eur. Acad. Dermatol. Venereol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.jaad.2012.06.014","article-title":"Liposomal amphotericin b in comparison to sodium stibogluconate for leishmania braziliensis cutaneous leishmaniasis in travelers","volume":"68","author":"Solomon","year":"2013","journal-title":"J. Am. Acad. Dermatol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"H1319","DOI":"10.1152\/ajpheart.2000.279.3.H1319","article-title":"Liposome-induced pulmonary hypertension: properties and mechanism of a complement-mediated pseudoallergic reaction","volume":"279","author":"Szebeni","year":"2000","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0001656","article-title":"Prediction score for antimony treatment failure in patients with ulcerative leishmaniasis lesions","volume":"6","author":"Valencia","year":"2012","journal-title":"PLoS Negl. Trop. Dis."},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0050067","article-title":"Observational research, randomised trials, and two views of medical science","volume":"5","author":"Vandenbroucke","year":"2008","journal-title":"PLoS Med."},{"key":"B49","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.diagmicrobio.2013.04.001","article-title":"Nephrotoxicity and other adverse events among inpatients receiving liposomal amphotericin b or amphotericin b lipid complex","volume":"76","author":"Wade","year":"2013","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"B50","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1056\/NEJM199903113401004","article-title":"Liposomal amphotericin b for empirical therapy in patients with persistent fever and neutropenia","volume":"340","author":"Walsh","year":"1999","journal-title":"New Engl. J. Med."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1002\/jps.2600830716","article-title":"Decreased toxicity of liposomal amphotericin b due to association of amphotericin b with high-density lipoproteins","volume":"83","author":"Wasan","year":"1994","journal-title":"J. Pharm. Sci."},{"key":"B52","unstructured":"LeishmaniasisWorld Health organizationWorld health organization webpage newsroom2021"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.4269\/ajtmh.2010.10-0171","article-title":"Lipsosomal amphotericin b for treatment of cutaneous leishmaniasis","volume":"83","author":"Wortmann","year":"2010","journal-title":"Am. J. Trop. Med. Hygiene"},{"key":"B54","doi-asserted-by":"publisher","first-page":"692","DOI":"10.4269\/ajtmh.2011.10-0712","article-title":"Case report: Successful treatment of cutaneous leishmaniasis caused by leishmania aethiopica with liposomal amphothericin b in an immunocompromised traveler returning from Eritrea","volume":"84","author":"Zanger","year":"2011","journal-title":"Am. J. Trop. Med. Hygiene"}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2022.993338\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T11:10:36Z","timestamp":1663931436000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2022.993338\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,23]]},"references-count":54,"alternative-id":["10.3389\/fcimb.2022.993338"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2022.993338","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,23]]},"article-number":"993338"}}